Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | MAT2A | P31153 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30039575 | 1.00 | HCAR3 (0.44) | HCAR3SLC22A12KDM4ECSNK2A1MAT2A | |
| SCHEMBL23535848 | 0.84 | ALDH1A1 (0.41) | KDM4EHPGDALDH1A1 | |
| SCHEMBL30040748 | 0.84 | ALDH1A1 (0.41) | KDM4EHPGDALDH1A1 | |
| SCHEMBL30159550 | 0.81 | HCAR3 (0.36) | HCAR3SLC22A12KDM4ECSNK2A1RORC | |
| SCHEMBL23535658 | 0.81 | HCAR3 (0.36) | HCAR3SLC22A12KDM4ECSNK2A1RORC | |
| SCHEMBL17785249 | 0.80 | HCAR3 (0.47) | HCAR3SLC22A12KDM4EHPGDALDH1A1 | |
| SCHEMBL4509480 | 0.80 | SLC22A12 (0.57) | HCAR3SLC22A12KDM4E | |
| SCHEMBL30040324 | 0.80 | SLC22A12 (0.57) | HCAR3SLC22A12KDM4E | |
| SCHEMBL23559591 | 0.78 | HCAR3 (0.46) | HCAR3SLC22A12KDM4EHPGDALDH1A1 | |
| SCHEMBL31632926 | 0.78 | HCAR3 (0.46) | HCAR3SLC22A12KDM4EHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| CN-115427035-A | ENL/AF9YEATS inhibitors | 洛克菲勒大学 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021127166-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127166-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | MLLT3, YEATS2, MLLT1 | HCAR3 1553/4885SLC22A12 2634/4885KDM4E 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.